Trial · NCT00982488
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Chronic Phase | All deaths | 22 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Imatinib, 400 mg BID, Chronic Phase | All deaths | 0 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, AP | All deaths | 4 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, MBP | All deaths | 0 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, Ph+ ALL | All deaths | 0 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Chronic Phase | Deaths within 30 days of last dose | 9 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Imatinib, 400 mg BID, Chronic Phase | Deaths within 30 days of last dose | 0 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, AP | Deaths within 30 days of last dose | 2 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, MBP | Deaths within 30 days of last dose | 0 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, Ph+ ALL | Deaths within 30 days of last dose | 0 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Chronic Phase | SAEs | 57 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Imatinib, 400 mg BID, Chronic Phase | SAEs | 3 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, AP | SAEs | 15 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, MBP | SAEs | 1 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, Ph+ ALL | SAEs | 1 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Chronic Phase | Drug-related SAEs | 28 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Imatinib, 400 mg BID, Chronic Phase | Drug-related SAEs | 2 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, AP | Drug-related SAEs | 9 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, MBP | Drug-related SAEs | 0 | Participants | |
Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, Ph+ ALL | Drug-related SAEs | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00982488/results